IL15 and Burkitt lymphoma: Studies have shown that the combination of anti-CD20 or anti-CD79 antibodies with NKTR-255 (a polymer-conjugated, IL-15Rα-dependent, recombinant human IL-15 agonist) can significantly enhance the in vitro cytotoxicity of CD19-CAR-NK cells against Burkitt’s lymphoma (BL) cells (82).